ArticleCureus2025
An Integrative Analysis of O6-Methylguanine-DNA Methyltransferase (MGMT) Methylation and the Single-Nucleotide Polymorphism (SNP) rs1625649 Reveals Distinct Survival Patterns in Glioblastoma: A Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is an established predictive and prognostic biomarker in glioblastoma (GBM). However, the influence of MGMT promoter single-nucleotide polymorphisms (SNPs), particularly rs1625649, on gene expression and patient outcomes remains unclear. This study evaluated the prognostic impact of MGMT methylation and SNP rs1625649 in GBM patients. Methods This retrospective analytical study included 66 histologically confirmed GBM patients (IDH1 R132H-negative), treated at a tertiary care center from 2018 to 2022. MGMT methylation was assessed using methylation-specific PCR, and SNP rs1625649 genotyping was performed by PCR-restriction fragment length polymorphism (PCR-RFLP). Survival analyses were conducted using Kaplan-Meier and Cox proportional hazards models. Key clinical variables, including age, Karnofsky performance status (KPS), extent of resection, and treatment data, were analyzed. Results MGMT promoter methylation was present in 56.1% of cases and was significantly associated with longer overall survival (OS: 86.4 days (≈2.9 months) vs. 35.0 days (≈1.2 months); p < 0.001). The SNP rs1625649 AA genotype was observed in 15.2% of patients and was associated with prolonged OS (130.8 days) compared to CA (64.2 days) and CC (47.0 days) (p = 0.002). Among methylated cases, the AA genotype conferred superior survival (160.7 days; p = 0.009). Multivariate Cox analysis confirmed MGMT methylation (HR = 0.46; p = 0.005) and the rs1625649 AA genotype (HR = 0.41; p = 0.040) as independent prognostic factors. Conclusion MGMT promoter methylation and the SNP rs1625649 AA genotype are independently associated with improved survival in GBM. These findings highlight the potential prognostic utility of incorporating MGMT SNP genotyping alongside methylation status in clinical practice. Further large-scale studies are warranted to validate these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.